Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma
Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.
Reem Karmali, MD, assistant professor of medicine (hematology and oncology, Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (Yescarta; KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.
Related Videos
Related Content
